Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for non-cirrhotic NASH with stage 2-3 fibrosis
MOH_2021-01-24_009496Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Semaglutide once weekly with Placebo once weekly (2 arms). Primary endpoints: Part 1 histologic improvement and Part 2 liver-related clinical events. Started Jan 2021; status: active, not recruiting.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on MOH_2021-01-24_009496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-01-24_009496.